GXHPC 1
Alternative Names: Adipose-derived-stem-cells-Gwo-Xi; ADSC-Gwo-Xi; GXHPC1; GXHPC1 - Gwo Xi Stem Cell Applied TechnologyLatest Information Update: 25 Jul 2022
At a glance
- Originator GWOXI Stem Cell Applied Technology
- Class Hepatoprotectants; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Liver cirrhosis
Most Recent Events
- 25 Jul 2022 GXHPC 1 is still in phase II trials for Liver cirrhosis (In adults, In the elderly) in Taiwan (Intrahepatic) (GWOXI Stem Cell Applied Technology pipeline, July 2022)
- 17 Feb 2020 Phase-II clinical trials in Liver cirrhosis (In the elderly, In adults) in Taiwan (Intrahepatic) (NCT04088058)
- 17 Sep 2019 Gwo Xi Stem Cell Applied Technology plans a phase II trial for Liver Cirrhosis in November 2019 (NCT04088058)